

Lamivudine + zidovudine



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

EMLc

ATC codes: [J05AR01](#)

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z
INN	Lamivudine + zidovudine
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 30 mg + 60 mg Tablet (EMLc) ; 150 mg + 300 mg Tablet (EML)
EML status history	First added in 2007 (TRS 946) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . ↗
Wikipedia	Lamivudine + zidovudine ↗
DrugBank	Lamivudine ↗ , Zidovudine ↗

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the removal of lamivudine + zidovudine 150 mg + 300 mg from the EMLc to be in alignment with the recommendations of the Inter-Agency Task Team on Prevention and treatment of HIV in Pregnant Women, Mothers and their Children (1). References: 1. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland, 11-12 September 2013 Geneva: World Health Organization; 2013. Available from: <http://apps.who.int/medicinedocs/documents/s21435en/s21435en.pdf>.

